Protective Assets Reinforced With Integrated Care and TechnologY (PARITY) Feasibility Trial
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Detailed Description
Study Type
Study Type
Enrollment (Actual)
Enrollment
Phase
Phase
- Not Applicable
Contacts and Locations
Study Contact
Study Contact
- Name: Elizabeth K Mollard, PhD
- Phone Number: 402-472-3665
- Email: elizabeth.mollard@unmc.edu
Study Locations
-
-
Nebraska
-
Omaha, Nebraska, United States, 68198
- University of Nebraska Medical Center
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- Black race
- Pregnant with gestational age 20-28 weeks at enrollment
- Ability to read and write in English language
- Planning to give birth at a healthcare facility & receive obstetrical care with a healthcare record
- Reside within 20 minutes of the Lincoln/Omaha, NE metro area
- Owns a smartphone with internet access
Exclusion Criteria:
-
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Prevention
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Number of Arms
Arms and Interventions
Participant Group / ArmParticipant Group / Arm |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
Experimental: PARITY
Participants will take part in the Protective Assets Reinforced with Integrated care and TechnologY (PARITY) program which is community-based doula support, community resources, and a mobile technology platform that reinforces individual strengths through positive messaging and by promoting wellness (sleep, physical activity, nutrition, prenatal care adherence) in Black pregnant women.
|
The PARITY program reinforces strengths through consistent, community-based Black doula support and protective asset (personal strengths) focused messaging.
PARITY promotes wellness-related behaviors (nutrition, physical activity, sleep, and healthcare adherence) and promotes and builds empowered strengths (self-efficacy, social support, motivation, resilience, problem-solving, and self-regulation) through mobile technology and doula support.
Participants will obtain prenatal care from their usual care provider and a handout on healthy pregnancy.
|
|
Placebo Comparator: Control
Participants will obtain prenatal care from their usual care provider and a handout on healthy pregnancy.
|
Participants will obtain prenatal care from their usual care provider and a handout on healthy pregnancy.
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Maternal Blood Pressure
Time Frame: 20 weeks
|
Participant blood pressure (systolic and diastolic) (continuous) as well as blood pressure classifications hypertension (>140/90); Severe hypertension (>160/110).
|
20 weeks
|
|
Maternal Blood Pressure
Time Frame: 36 weeks
|
Participant blood pressure (systolic and diastolic) (continuous) as well as blood pressure classifications hypertension (>140/90); Severe hypertension (>160/110).
|
36 weeks
|
|
Maternal Blood Pressure
Time Frame: Birth (approximately 36-42 weeks)
|
Participant blood pressure (systolic and diastolic) (continuous) as well as blood pressure classifications hypertension (>140/90); Severe hypertension (>160/110).
|
Birth (approximately 36-42 weeks)
|
|
Maternal Blood Pressure
Time Frame: 6-12 weeks postpartum
|
Participant blood pressure (systolic and diastolic) (continuous) as well as blood pressure classifications hypertension (>140/90); Severe hypertension (>160/110).
|
6-12 weeks postpartum
|
|
Feasibility, Enrollment
Time Frame: Baseline
|
Percentage of eligible individuals who agree to participate in the trial
|
Baseline
|
|
Feasibility, Attrition
Time Frame: Completion of Study (~24 months)
|
Percentage of eligible individuals who complete the data
|
Completion of Study (~24 months)
|
|
Feasibility, Adherence
Time Frame: Completion of Study (~24 months)
|
Number of intervention sessions completed by study participants
|
Completion of Study (~24 months)
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Gestational Weight Gain
Time Frame: 20 weeks, 36 weeks, Birth, 6 weeks postpartum.
|
Amount of weight gained in pounds
|
20 weeks, 36 weeks, Birth, 6 weeks postpartum.
|
|
Delivery Modality
Time Frame: Birth (approximately 36-42 weeks)
|
Modality of birth (Vaginal, Cesarean, Assisted Vaginal delivery)
|
Birth (approximately 36-42 weeks)
|
Other Outcome Measures
Other Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Nutritional Intake
Time Frame: Baseline, 6-12 weeks postpartum
|
Nutritional intake will be measured with the Multifactor Screener, 2000 as used in the Observing Protein and Energy Nutrition (OPEN) Study.
This instrument measures approximate intakes of fruits and vegetables, percentage energy from fat, and fiber.
Respondents report how frequently they consume foods in 16 categories and type of milk consumed.
|
Baseline, 6-12 weeks postpartum
|
|
Physical Activity
Time Frame: Baseline, 6-12 weeks postpartum
|
Physical activity will be measured with the International Physical Activity Questionnaire short-form (IPAQ-SF).
The IPAQ-SF consists of 9 items and provides information on the time spent walking, in vigorous and moderate intensity activity and in sedentary activity.
|
Baseline, 6-12 weeks postpartum
|
|
Sleep quality
Time Frame: Baseline, 6-12 weeks postpartum
|
Sleep quality will be measured using the Pittsburgh Sleep Quality Index (PSQI.
The PSQI is a self-report questionnaire that assesses sleep quality over a 1-month time interval.
The measure consists of 19 individual items, creating 7 components that produce one global score.
|
Baseline, 6-12 weeks postpartum
|
|
Healthcare Adherence
Time Frame: Pregnancy continuum, measured at 12 weeks postpartum retrospectively via the medical record
|
Healthcare adherence will be measured by number of healthcare appointments measured in the medical record.
|
Pregnancy continuum, measured at 12 weeks postpartum retrospectively via the medical record
|
|
Self-efficacy
Time Frame: Baseline, 6-12 weeks postpartum
|
Self-efficacy will be measured using the GSE General Self Efficacy (GSE) Scale: The GSE is a one-dimensional self-report measure that features a 10-item questionnaire assessing the optimistic self-beliefs of individuals to cope with a variety of difficult demands in life.
The response options are presented along a 4-point Likert scale for each item.
|
Baseline, 6-12 weeks postpartum
|
|
Social support
Time Frame: Baseline, 6-12 weeks postpartum
|
Social support will be measured with the 10 item Social Provisions Scale (SPS-10).
The SPS-10 assesses five forms of social provisions: attachment, guidance, social integration, reliable alliance, and reassurance of worth.
Each item is rated on a four-point Likert scale.
|
Baseline, 6-12 weeks postpartum
|
|
Problem-solving
Time Frame: Baseline, 6-12 weeks postpartum
|
Problem solving will be measured with the Problem-Solving Inventory (PSI).
The PSI measures how well individuals make decisions and their problem-solving abilities.
The PSI includes 32 items using a 6-point Likert scale.
|
Baseline, 6-12 weeks postpartum
|
|
Motivation
Time Frame: Baseline, 6-12 weeks postpartum
|
Motivation will be measured with the Self-Motivation Inventory (SMI).
The SMI is a 40 item 5 point Likert scale.
|
Baseline, 6-12 weeks postpartum
|
|
Resilience
Time Frame: Baseline, 6-12 weeks postpartum
|
Resilience will be measured using the 10 item Connor-Davidson Resilience Scale (CD-RISC 10).
The CD-RISC 10 a unidimensional self-reported scale consisting of 10-items measuring resilience.
Respondents rate items on a 5-point Likert scale.
|
Baseline, 6-12 weeks postpartum
|
|
Self-Regulation
Time Frame: Baseline, 6-12 weeks postpartum
|
Self-Regulation will be measured with the index of self-regulation (ISR).
The ISR is a nine-item scale that measures level of self-regulation for health behavior change.
Respondents rate items on a 5-point Likert scale.
|
Baseline, 6-12 weeks postpartum
|
|
Discrimination
Time Frame: Baseline, 6-12 weeks postpartum
|
Discrimination will be measured using the Everyday Discrimination Scale (EDS).
The EDS measures frequency of chronic and routine unfair treatment in everyday life.
Respondents are asked to report how often they experience unfair treatment in their day-to-day life on a 6-point Likert scale.
|
Baseline, 6-12 weeks postpartum
|
|
Neighborhood
Time Frame: Baseline
|
Neighborhood will be assessed using the Neighborhood Collective Efficacy - Community Cohesion and Informal Social Control protocol.
This protocol includes 10 Likert-style questions from the Project on Human Development in Chicago Neighborhoods (PHDCN).
The Social Cohesion and Informal Social Control subscales include five items each.
|
Baseline
|
|
Acceptability and Experience
Time Frame: 12 weeks postpartum
|
Select intervention participants only (10-15).
Qualitative interview to discuss acceptability and experience with the intervention.
|
12 weeks postpartum
|
Collaborators and Investigators
Sponsor
Sponsor
Investigators
Investigators
- Principal Investigator: Elizabeth K Mollard, PhD, University of Nebraska
Publications and helpful links
Study record dates
Study Major Dates
Study Start (Actual)
Study Start
Primary Completion (Actual)
Primary Completion
Study Completion (Actual)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Actual)
First Posted
Study Record Updates
Last Update Posted (Actual)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
Other Study ID Numbers
- 0076-23-EP
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.